Maria Düring

2.6k total citations · 1 hit paper
23 papers, 2.1k citations indexed

About

Maria Düring is a scholar working on Cancer Research, Molecular Biology and Surgery. According to data from OpenAlex, Maria Düring has authored 23 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 9 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Maria Düring's work include Breast Cancer Treatment Studies (9 papers), Diabetes Treatment and Management (8 papers) and Metabolism, Diabetes, and Cancer (7 papers). Maria Düring is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), Diabetes Treatment and Management (8 papers) and Metabolism, Diabetes, and Cancer (7 papers). Maria Düring collaborates with scholars based in Denmark, United States and United Kingdom. Maria Düring's co-authors include Kjeld Hermansen, Michael A. Nauck, Anders Frid, David R. Matthews, Tsvetalina Tankova, Ismail Mitha, Nalini S. Shah, Milan Zdravković, Henning T. Mouridsen and Susanne Möller and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Diabetes Care.

In The Last Decade

Maria Düring

23 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

2008 939 citations Michael A. Nauck, Anders Frid et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Düring Denmark	13	1.3k	791	643	395	384	23	2.1k
Annie St‐Pierre Canada	12	486 0.4×	510 0.6×	451 0.7×	184 0.5×	353 0.9×	22	1.4k
J. Atkins United States	12	472 0.4×	415 0.5×	285 0.4×	397 1.0×	625 1.6×	19	2.3k
Kashif Jafri United States	10	862 0.7×	308 0.4×	968 1.5×	300 0.8×	119 0.3×	13	1.9k
Christian M. Madsen Denmark	25	842 0.6×	263 0.3×	1.5k 2.4×	420 1.1×	112 0.3×	50	2.3k
Vivian T. Thieu United States	18	874 0.7×	457 0.6×	319 0.5×	45 0.1×	157 0.4×	44	1.7k
Jorie Versmissen Netherlands	21	399 0.3×	308 0.4×	855 1.3×	331 0.8×	184 0.5×	94	2.0k
Ikunosuke Sakurabayashi Japan	19	580 0.4×	351 0.4×	836 1.3×	236 0.6×	80 0.2×	122	1.7k
Connie M. Szczepanek United States	6	449 0.3×	306 0.4×	232 0.4×	282 0.7×	238 0.6×	10	1.8k
C. J. Currie United Kingdom	10	687 0.5×	821 1.0×	256 0.4×	205 0.5×	386 1.0×	15	1.4k
Cathee Till United States	27	254 0.2×	351 0.4×	200 0.3×	421 1.1×	539 1.4×	71	2.0k

Countries citing papers authored by Maria Düring

Since Specialization

Citations

This map shows the geographic impact of Maria Düring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Düring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Düring more than expected).

Fields of papers citing papers by Maria Düring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Düring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Düring. The network helps show where Maria Düring may publish in the future.

Co-authorship network of co-authors of Maria Düring

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Düring. A scholar is included among the top collaborators of Maria Düring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Düring. Maria Düring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mora, Jaume, Gcf Chan, Daniel A. Morgenstern, et al.. (2025). The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial. Nature Communications. 16(1). 1636–1636. 3 indexed citations

Mora, Jaume, Godfrey Chi Fung Chan, Daniel A. Morgenstern, et al.. (2024). Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.. Journal of Clinical Oncology. 42(16_suppl). 10032–10032. 2 indexed citations

Owonikoko, Taofeek K., Justin C. Moser, Janet Yoon, et al.. (2023). Phase 1 trial of GD2-SADA:¹⁷⁷Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.. Journal of Clinical Oncology. 41(16_suppl). TPS3162–TPS3162. 3 indexed citations

Hermansen, Kjeld, Tine A. Bækdal, Maria Düring, et al.. (2012). Liraglutide Suppresses Postprandial Triglyceride (TG) and Apolipoprotein B48 (ApoB48) Responses to a Fat-Rich Meal in Patients with Type 2 Diabetes. Canadian Journal of Diabetes. 36(5). S35–S35. 1 indexed citations

Nauck, Michael A., Anders Frid, Kjeld Hermansen, et al.. (2012). Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD ‐2 study. Diabetes Obesity and Metabolism. 15(3). 204–212. 121 indexed citations

Jendle, Johan, Michael A. Nauck, David R. Matthews, et al.. (2009). Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obesity and Metabolism. 11(12). 1163–1172. 247 indexed citations

Hölmich, Lisbet Rosenkrantz, Maria Düring, Trine Foged Henriksen, et al.. (2008). Delayed Breast Reconstruction With Implants After Invasive Breast Cancer Does Not Impair Prognosis. Annals of Plastic Surgery. 61(1). 11–18. 26 indexed citations

Hermansen, Kjeld, Michael A. Nauck, Anders Frid, et al.. (2008). Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin. Lund University Publications (Lund University). 2 indexed citations

Blichert-Toft, M, Maja Nielsen, Maria Düring, et al.. (2008). Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncologica. 47(4). 672–681. 213 indexed citations

10.

Ewertz, Marianne, Maria Düring, Maj‐Britt Jensen, et al.. (2008). Breast conserving treatment in Denmark, 1989–1998. A nationwide population-based study of the Danish Breast Cancer Co-operative Group.. Acta Oncologica. 47(4). 682–690. 16 indexed citations

11.

Frid, Anders, Michael A. Nauck, Kjeld Hermansen, et al.. (2008). Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycem1c Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin.. Canadian Journal of Diabetes. 32(4). 329–329. 12 indexed citations

12.

Nauck, Michael A., Anders Frid, Kjeld Hermansen, et al.. (2008). Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Diabetes Care. 32(1). 84–90. 939 indexed citations breakdown →

13.

Axelsson, C. K., et al.. (2008). Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. British journal of surgery. 96(1). 40–46. 18 indexed citations

14.

Dalton, Susanne Oksbjerg, Lone Ross, Maria Düring, et al.. (2007). Influence of socioeconomic factors on survival after breast cancer—A nationwide cohort study of women diagnosed with breast cancer in Denmark 1983–1999. International Journal of Cancer. 121(11). 2524–2531. 64 indexed citations

15.

Düring, Maria, et al.. (2007). Prognostic effect of estrogen receptor status across age in primary breast cancer. International Journal of Cancer. 122(5). 1089–1094. 123 indexed citations

16.

Axelsson, C. K., Henning T. Mouridsen, Maria Düring, & Susanne Möller. (2007). Axillary staging during surgery for breast cancer. British journal of surgery. 94(3). 304–309. 11 indexed citations

17.

Dalton, Susanne Oksbjerg, Maria Düring, Lone Ross, et al.. (2006). The relation between socioeconomic and demographic factors and tumour stage in women diagnosed with breast cancer in Denmark, 1983–1999. British Journal of Cancer. 95(5). 653–659. 70 indexed citations

18.

Knoop, Ann, Helle Knudsen, Eva Balslev, et al.. (2006). TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D). Journal of Clinical Oncology. 24(18_suppl). 532–532. 10 indexed citations

19.

Düring, Maria, et al.. (2005). Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). British Journal of Cancer. 93(6). 627–632. 96 indexed citations

20.

Jong, J.C. de, et al.. (1994). Community-based study of the incidence of gastrointestinal diseases in The Netherlands. Epidemiology and Infection. 112(3). 481–487. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact